Targeting PPARγ and its downstream pathways offers translational potential for the treatment of obesity and metabolic disorders by enhancing energy expenditure and insulin sensitivity, although adverse effects of synthetic agonists limit their long-term clinical use [52,53,54,55,56,57,58,59]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.